JP2023548556A5 - - Google Patents

Info

Publication number
JP2023548556A5
JP2023548556A5 JP2023527029A JP2023527029A JP2023548556A5 JP 2023548556 A5 JP2023548556 A5 JP 2023548556A5 JP 2023527029 A JP2023527029 A JP 2023527029A JP 2023527029 A JP2023527029 A JP 2023527029A JP 2023548556 A5 JP2023548556 A5 JP 2023548556A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
tcr
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023527029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548556A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/058019 external-priority patent/WO2022098845A1/en
Publication of JP2023548556A publication Critical patent/JP2023548556A/ja
Publication of JP2023548556A5 publication Critical patent/JP2023548556A5/ja
Pending legal-status Critical Current

Links

JP2023527029A 2020-11-05 2021-11-04 Egfr抗原を標的とする操作されたt細胞受容体および使用方法 Pending JP2023548556A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063110116P 2020-11-05 2020-11-05
US63/110,116 2020-11-05
PCT/US2021/058019 WO2022098845A1 (en) 2020-11-05 2021-11-04 Engineered t cell receptors targeting egfr antigens and methods of use

Publications (2)

Publication Number Publication Date
JP2023548556A JP2023548556A (ja) 2023-11-17
JP2023548556A5 true JP2023548556A5 (cg-RX-API-DMAC7.html) 2024-11-12

Family

ID=81458279

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023527029A Pending JP2023548556A (ja) 2020-11-05 2021-11-04 Egfr抗原を標的とする操作されたt細胞受容体および使用方法

Country Status (6)

Country Link
US (1) US20240009241A1 (cg-RX-API-DMAC7.html)
EP (2) EP4240377A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023548556A (cg-RX-API-DMAC7.html)
KR (1) KR20230104220A (cg-RX-API-DMAC7.html)
CA (1) CA3200661A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022098845A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4227316A4 (en) * 2020-10-07 2025-07-30 Daan Biotherapeutics Co., Ltd. T CELL RECEPTOR, IMMUNE CELL COMPRISING T CELL RECEPTOR, AND METHOD USING THE SAME
WO2024054863A1 (en) * 2022-09-06 2024-03-14 Board Of Regents, The University Of Texas System T-cell receptor that targets egfr mutation and methods of using the same
US20260201034A1 (en) * 2022-12-05 2026-07-16 Board Of Regents, The University Of Texas System A t cell receptor recognizing a her2 mutation presented on hla-a*02:01 and methods of use
WO2026011097A1 (en) * 2024-07-03 2026-01-08 Yale University Antibody drug conjugates comprising tcr-vbeta specific therapeutic molecules and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
DK0604662T3 (da) 1992-07-07 2008-10-20 Japan Tobacco Inc Fremgangsmåde til transformering af monocotyledon
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
AU670316B2 (en) 1992-07-27 1996-07-11 Pioneer Hi-Bred International, Inc. An improved method of (agrobacterium)-mediated transformation of cultured soybean cells
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
JP2001508302A (ja) 1997-01-10 2001-06-26 ライフ テクノロジーズ,インコーポレイテッド 胚性幹細胞血清置換
EP0970128A1 (en) 1997-03-21 2000-01-12 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
JP2014022858A (ja) 2012-07-17 2014-02-03 Murata Mfg Co Ltd 電力増幅器
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
EP3572510B1 (en) * 2013-11-21 2022-09-21 Repertoire Genesis Incorporation T cell receptor and b cell receptor repertoire analysis system, and use of same in treatment and diagnosis
PL3177643T3 (pl) 2014-08-04 2019-09-30 F.Hoffmann-La Roche Ag Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T
EP3310811B1 (en) 2015-06-16 2021-06-16 Genentech, Inc. Anti-cd3 antibodies and methods of use
SG11201807489PA (en) * 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
KR20190062505A (ko) * 2016-10-03 2019-06-05 주노 쎄러퓨티크스 인코퍼레이티드 Hpv-특이적 결합 분자
MX2020001879A (es) * 2017-08-18 2020-07-29 Gritstone Oncology Inc Proteínas de fijación al antígeno que se dirigen a antígenos compartidos.
US20220175899A1 (en) * 2019-04-11 2022-06-09 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer
CN111848782A (zh) * 2019-04-25 2020-10-30 天津亨佳生物科技发展有限公司 一种针对egfr l858r基因突变的特异性t细胞受体及其应用
US20220213167A1 (en) * 2019-05-03 2022-07-07 Gigamune, Inc. Engineered cells expressing anti-tumor t cell receptors and methods of use thereof

Similar Documents

Publication Publication Date Title
US10118964B2 (en) Construction and application of bispecific antibody HER2xCD3
JP7595696B2 (ja) Cd3抗原結合性断片及びその使用
US9777073B2 (en) Construction and application of bispecific antibody EpCAM×CD3
JP2022058776A (ja) 系統特異的抗原の阻害のための組成物および方法
JP2023528255A5 (cg-RX-API-DMAC7.html)
CN104592392B (zh) 一种双特异性抗体EpCAM×CD3的构建及应用
CN106397593A (zh) 抗磷脂酰肌醇蛋白多糖‑3的抗体及其应用
CN118580363A (zh) 制导和导航控制蛋白及其制备和使用方法
CN104592391B (zh) 一种双特异性抗体EpCAM×CD3的构建及应用
CN115232209A (zh) 靶向gprc5d的抗体及其用途
CN104788567A (zh) 一种靶向鼠T淋巴细胞CD3和人肿瘤抗原EpCAM的双特异性抗体制备方法及应用
CN109705225B (zh) 一种抗人caix抗原的嵌合抗原受体及其应用
CN104829725A (zh) 一种双特异性抗体cd133×cd3的构建及应用
KR20210132668A (ko) 인공 면역감시 키메라 항원 수용체(ai-car) 및 이를 발현하는 세포
WO2023051414A1 (zh) 靶向间皮素的抗体及其用途
CN117924519A (zh) 靶向cd138的嵌合抗原受体
CN111848806B (zh) Egfr-cd3双功能抗体及其应用
CN110872356B (zh) 双特异性抗体及其使用方法
CN104288765A (zh) 一种利用具有中和FLT3生物学活性的McAb应用于肿瘤的靶向治疗的新方法
CN117425493A (zh) 用于治疗肺癌的组合物和方法
CN104558193A (zh) 一种靶向鼠t淋巴细胞cd3和人肿瘤抗原her2的双特异性抗体制备方法及应用
JP2023530245A5 (cg-RX-API-DMAC7.html)
CN111434691A (zh) Pd-l2单克隆抗体及其应用
CN103965359B (zh) 抗上皮细胞粘附分子和t细胞抗原的双特异性抗体
CN118126194A (zh) 靶向cd70的嵌合抗原受体